首页> 外文会议>International symposium on controlled release of bioactive materials;Consumer and diversified products conference >Preparation and characterization of a surfactant-protein-(sp-) b-urokinase conjugate for targeting fibrinolytic activity to surfactant containing clots
【24h】

Preparation and characterization of a surfactant-protein-(sp-) b-urokinase conjugate for targeting fibrinolytic activity to surfactant containing clots

机译:表面活性剂-蛋白质-(sp-)b-尿激酶缀合物的制备和表征,用于将纤溶活性靶向于含凝块的表面活性剂

获取原文

摘要

Intraalveolar accumulation of fibrin rich material (_"hyaline membranes") is a hallmark of acute and chronic inflammatory lung diseases, includig ALI (acute lung injury) and ARDS (adult respiratory distress syndrome) (1)> Markedly increased procoagulant activities of the alveolar space, mainly attributable to the extrinsic pathway enzymes tissue factor and FVII, and depressed fibrinolytic capacities were found under inflammatory conditions 92). Fibrinogen leaking into the alveolar space due to an impaired capillary-endothelial and alveo-epithelial barrier function may thus be rapidly converted into fibrin. It was recently discovered, that polymerizing fibrin effects a severe loss of surfactant function by incorporating hydrophobic surfactant constituents (phospholipids, SP-B) (3). In vitro experiments revealed that fibrin clots embedding natural surfactant displayed markedly altered mechanical properties, and were less susceptable towards proteolysis by plasmin, trypsin or elastase. However complete lysis of such surfactant incorporating fibrin clots was noted to result in the liberation of intact surfactant material and marked improvement in surface tension properties (4,5). Dissolution of alveolar fibrin may thus represent an important feature for recovery from acute lung injury and prevention of fibrotic events. For targeting surfactant-containing closts, we constructed a hybridmolecule consisting of SP-B and the B-chain of urokinase (SPUC), and investigated in vitro the fibrinolytic and biophysical activities.
机译:肺泡内富含纤维蛋白的物质(“透明膜”)是急性和慢性炎症性肺疾病,包括ALI(急性肺损伤)和ARDS(成人呼吸窘迫综合征)的标志(1)>肺泡的促凝活性显着增加空间,主要归因于外在途径酶组织因子和FVII,并发现在炎症条件下纤维蛋白溶解能力下降(92)。因此,由于毛细血管内皮和肺上皮屏障功能受损而渗入肺泡腔的纤维蛋白原可迅速转变为纤维蛋白。最近发现,聚合纤维蛋白会通过掺入疏水性表面活性剂成分(磷脂,SP-B)而严重破坏表面活性剂功能(3)。体外实验表明,包埋天然表面活性剂的血纤蛋白凝块显示出明显改变的机械性能,并且对纤溶酶,胰蛋白酶或弹性蛋白酶的蛋白水解敏感性较小。然而,注意到掺入了纤维蛋白凝块的这种表面活性剂的完全裂解导致完整表面活性剂材料的释放和表面张力性质的显着改善(4,5)。因此,肺泡纤维蛋白的溶解可能代表了从急性肺损伤中恢复和预防纤维化事件的重要特征。为了靶向含表面活性剂的凝块,我们构建了由SP-B和尿激酶B链(SPUC)组成的杂化分子,并在体外研究了纤维蛋白溶解和生物物理活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号